Tim Schlidt is the co-founder of psychedelic-focused VC fund Palo Santo. He is one of the leading voices pushing for the development of psychedelic-backed mental health therapies and has deployed over $25 million into 20 companies. Schlidt is also pushing for the FDA approval of psychedelic-assisted therapies to make them more accessible, affordable, and safe for patients suffering from treatment-resistant depression. 

In this episode of Hone In, Saad sits down with him to talk about what goes down during a therapeutic trip, ongoing clinical trials, and the growing acceptance of psychedelics in mental health care.

This conversation is an absolute game-changer. It walks the tightrope between scientific inquiry and personal experiences, offering you a comprehensive understanding of the profound potential of therapeutic psychedelics. 

WE DISCUSS:

How psychedelics can promote neuroplasticity

Anti-inflammatory and longevity benefits of psychedelics

MDMA and psilocybin (molly and mushrooms) for treatment-resistant depression

Tim's own experience with severe depression 

The mental health benefits of “ego death”

IN THIS EPISODE YOU'LL LEARN:

The difference between a psychedelic microdose and a macrodose

Why psychedelics could yield better results than SSRIs

When to expect FDA approval of psychedelic therapies

How much psychedelic-assisted therapy costs

And more

Check out all the episodes at: : https://honehealth.com/edge/podcast/ 

Listen to the episodes on:

SPOTIFY: https://open.spotify.com/show/76Hg5OU5oOu7S9Ze6WPSlw 

APPLE PODCASTS: https://podcasts.apple.com/us/podcast/hone-in/id1707026738 

Watch clips from Hone In episodes on: YouTube: https://www.youtube.com/watch?v=JoOQaVPbgKQ 

Get exclusive weekly tips from show guests in our newsletter:: https://hone-health.ck.page/hone-in 

Follow us at:

HONE HEALTH INSTAGRAM: https://www.instagram.com/hone.health/?hl=en 

SAAD ALAM INSTAGRAM: https://www.instagram.com/msaadalam/?hl=en 

Learn More: https://honehealth.com/